REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat lymphoma: targeted drug combo shows promise in late-stage trial
Disease control OngoingThis study tests whether adding a targeted drug (polatuzumab vedotin) to standard chemotherapy can help people with diffuse large B-cell lymphoma that has returned or not responded to initial treatment. About 306 adults will receive either the new combination or standard therapy.…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated May 17, 2026 04:27 UTC
-
New drug combo shows promise for Tough-to-Treat lymphoma
Disease control OngoingThis early-stage study tests the safety and best dose of two drugs—ibrutinib and lenalidomide—given together to people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The goal is to find a dose that is safe and tolerable, while also seeing …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:17 UTC
-
New hope for tough blood cancers: experimental drug enters human testing
Disease control OngoingThis early-stage trial tests a new drug called BGB-21447 in about 112 people whose B-cell blood cancers (like lymphoma or leukemia) have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 17, 2026 04:13 UTC
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work togethe…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New hope for hard-to-treat lymphoma: drug duo tested in major trial
Disease control OngoingThis study tests whether a new combination of two drugs (loncastuximab tesirine and rituximab) works better than standard chemotherapy for people with diffuse large B-cell lymphoma that has returned or not improved after initial treatment. About 440 adults will take part. The mai…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
Real-World data shows Epcoritamab's promise for Tough-to-Treat lymphoma
Disease control OngoingThis study tracks how well the drug epcoritamab works for 150 adults whose diffuse large B-cell lymphoma has come back or not responded to at least two prior treatments. Researchers will measure tumor shrinkage and monitor side effects in a real-world setting outside of clinical …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Sponsor: Andrés José Maria Ferreri • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Two-Drug combo shows promise for Tough-to-Treat lymphomas
Disease control OngoingThis early-phase study tested a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and vorinostat (a drug that blocks enzymes cancer cells need to grow)—in 52 adults with certain types of lymphoma that had returned or stopped resp…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
Double-targeted cell therapy takes on hard-to-treat blood cancers
Disease control OngoingThis early-phase trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to recogniz…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:52 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New hope for hard-to-treat lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new combination of drugs (polatuzumab vedotin plus standard chemotherapy and immunotherapy) as the first treatment after lymphoma returns or doesn't respond. About 41 adults with diffuse large B-cell lymphoma will receive this therapy to see if it can shrink tu…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
New drug combo offers hope for Hard-to-Treat lymphoma
Disease control OngoingThis study tests a combination of two drugs, copanlisib and venetoclax, in people with diffuse large B-cell lymphoma that has come back or not responded to prior treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 48 adults will take pa…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
Supercharged immune cells take on tough lymphoma after transplant
Disease control OngoingThis early-phase trial tests a new approach for people with aggressive B-cell non-Hodgkin lymphoma that has come back after treatment. After a standard stem cell transplant, patients receive their own immune cells (T cells) that have been genetically modified in a lab to better r…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 08, 2026 12:01 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC
-
Promising lymphoma combo study pulled before it even started
Disease control TerminatedThis study planned to test a combination of three drugs (rituximab, venetoclax, and bortezomib) in adults with a type of aggressive lymphoma that had come back or stopped responding to standard treatment. The goal was to see if the combination could shrink or control the cancer. …
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New combo aims to boost CAR-T power against tough lymphoma
Disease control OngoingThis early-stage trial tests whether adding an experimental drug called NKTR-255 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has returned or not responded to treatment. The study involves about 27 adults and focuses on safety and…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
New combo tackles aggressive lymphoma that Won't quit
Disease control OngoingThis early-stage study tests a combination of four drugs (atezolizumab, gemcitabine, oxaliplatin, and rituximab) in about 24 people with a type of lymphoma that has come back or stopped responding to treatment. The main goals are to find the safest dose and see how well the drugs…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:17 UTC
-
New hope for tough lymphoma: drug combo shows promise in early trial
Disease control OngoingThis early-phase study tested a new combination of drugs (carfilzomib plus standard chemotherapy) in 29 adults with diffuse large B-cell lymphoma that had come back or not responded to prior treatment. The main goals were to find the safest dose of carfilzomib and see how well th…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC